No AccessJournal of UrologyReview article1 Dec 2007

Focal Therapy for Localized Prostate Cancer: A Critical Appraisal of Rationale and Modalities

    View All Author Information


    Based on contemporary epidemiological and pathological characteristics of prostate cancer we explain the rationale for and concerns about focal therapy for low risk prostate cancer, review potential methods of delivery and propose study design parameters.

    Materials and Methods:

    Articles regarding the epidemiology, diagnosis, imaging, treatment and pathology of localized prostate cancer were reviewed with a particular emphasis on technologies applicable for focal therapy, defined as targeted ablation of a limited area of the prostate expected to contain the dominant or only focus of cancer. A consensus summary was constructed by a multidisciplinary international task force of prostate cancer experts, forming the basis of the current review.


    In regions with a high prevalence of prostate specific antigen screening the over detection and subsequent overtreatment of prostate cancer is common. The incidence of unifocal cancers in radical prostatectomy specimens is 13% to 38%. In many others there is an index lesion with secondary foci containing pathological features similar to those found incidentally at autopsy. Because biopsy strategies and imaging techniques can provide more precise tumor localization and characterization, there is growing interest in focal therapy targeting unifocal or biologically unifocal tumors. The major arguments against focal therapy are multifocality, limited accuracy of staging, the unpredictable aggressiveness of secondary foci and the lack of established technology for focal ablation. Emerging technologies with the potential for focal therapy include high intensity focused ultrasound, cryotherapy, radio frequency ablation and photodynamic therapy.


    Early detection of prostate cancer has led to concerns that while many cancers now diagnosed pose too little a threat for radical therapy, many men are reluctant to accept watchful waiting or active surveillance. Several emerging technologies seem capable of focal destruction of prostate tissue with minimal morbidity. We encourage the investigation of focal therapy in select men with low risk prostate cancer in prospective clinical trials that carefully document safety, functional outcomes and cancer control.


    • 1 : The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol2004; 22: 2141. Google Scholar
    • 2 : Early stage prostate cancer—do we have a problem with over-detection, overtreatment or both?. J Urol2005; 173: 1061. LinkGoogle Scholar
    • 3 : Cancer incidence and mortality in Europe, 2004. Ann Oncol2005; 16: 481. Google Scholar
    • 4 : Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol2005; 35: 690. Google Scholar
    • 5 Cancer Facts and Figures. Atlanta, Georgia: American Cancer Society2006. Google Scholar
    • 6 : Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst2006; 98: 1134. Google Scholar
    • 7 Cancer Research UK, Information Research Centre. Available at Accessed July 9, 2006. Google Scholar
    • 8 : Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol2006; 24: 2137. Google Scholar
    • 9 : The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol1993; 150: 379. LinkGoogle Scholar
    • 10 : Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol2005; 174: 1785. LinkGoogle Scholar
    • 11 : Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol2003; 170: 1804. LinkGoogle Scholar
    • 12 : Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol2005; 23: 7881. Google Scholar
    • 13 : The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol2004; 172: 1297. LinkGoogle Scholar
    • 14 : Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol2006; 175: 902. LinkGoogle Scholar
    • 15 : Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer2004; 100: 2362. Google Scholar
    • 16 : Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology2002; 60: 264. Google Scholar
    • 17 : Increased prevalence of unifocal prostate cancer in a contemporary series of radical prostatectomy specimens: implications for focal ablation. J Urol2006; 175: 374. abstract 1163. LinkGoogle Scholar
    • 18 : Is focal therapy reasonable in patients with early stage prostate cancer (CaP)—an analysis of radical prostatectomy (RP) specimens. J Urol2006; 175: 507. suppl., abstract 1574. LinkGoogle Scholar
    • 19 : How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol2006; 50: 1163. Google Scholar
    • 20 : Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol2005; 174: 2158. LinkGoogle Scholar
    • 21 Shukla-Dave A, Hricak H, Kattan M, Pucar D, Kuroiwa K, Chen H et al: Predicting very low-risk prostate cancer with magnetic resonance: a new nomogram. Unpublished data. Google Scholar
    • 22 : Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology2006; 238: 597. Google Scholar
    • 23 : Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology2002; 223: 91. Google Scholar
    • 24 : Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol2006; 175: 939. LinkGoogle Scholar
    • 25 : The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. J Urol2005; 174: 2164. LinkGoogle Scholar
    • 26 : Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol2004; 171: 200. LinkGoogle Scholar
    • 27 : Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys2004; 59: 386. Google Scholar
    • 28 : The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol2005; 174: 1789. LinkGoogle Scholar
    • 29 : Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol2005; 174: 898. LinkGoogle Scholar
    • 30 : Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol2005; 18: 1022. Google Scholar
    • 31 : Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003; 170: 1792. LinkGoogle Scholar
    • 32 : Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol1997; 157: 223. LinkGoogle Scholar
    • 33 : Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol2007; 51: 381. Google Scholar
    • 34 : Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int2006; 97: 56. Google Scholar
    • 35 : Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol2003; 170: 1126. LinkGoogle Scholar
    • 36 : Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology2002; 60: 3. Google Scholar
    • 37 : Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology2002; 60: 109. Google Scholar
    • 38 : High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys2002; 53: 1111. Google Scholar
    • 39 : IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys2006; 65: 291. Google Scholar
    • 40 : Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J2000; 6: 249. Google Scholar
    • 41 : Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys2003; 57: 362. Google Scholar
    • 42 : High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol2004; 171: 1098. LinkGoogle Scholar
    • 43 : Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol2002; 168: 1427. LinkGoogle Scholar
    • 44 : Photodynamic therapy for urological malignancies: past to current approaches. J Urol2006; 175: 1201. LinkGoogle Scholar
    • 45 : Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol2005; 23: 826. Google Scholar
    • 46 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004; 351: 125. Google Scholar
    • 47 : Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol1996; 156: 1059. LinkGoogle Scholar
    • 48 : Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol2005; 173: 450. LinkGoogle Scholar
    • 49 : Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol2004; 171: 1093. LinkGoogle Scholar
    • 50 : Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol2002; 168: 1994. LinkGoogle Scholar